Global Cystatin C Assay Market, By Product (Analyzers, Kits & Reagents), Method (ELISA, PETIA, IFA, CLIA, PENIA), Application (Diagnostics, Research), Sample Type (Blood, Urine), End User (Hospitals, Clinical Laboratories, Others), Distribution Channel (Direct Tenders, Retail Sales) – Industry Trends and Forecast to 2031.
Cystatin C Assay Market Analysis and Size
As per the recent data chronic kidney disease (CKD) is becoming one of the world's most prevalent non-communicable chronic diseases. The World Health Organization projects CKD to become the 5th most common chronic disease in 2040. Similarly, it is a progressive condition that affects >10% of the general population worldwide, amounting to >800 million individuals. As per the Pan American Health Organization 2021. In 2019, regionwide kidney diseases account for, 254,028 total deaths, 131,008 deaths in men, and 123,020 deaths in women. The age-standardized death rate due to kidney diseases was estimated at 15.6 deaths per 100,000 population. In addition, more than 850 million individuals have kidney diseases worldwide.
Data Bridge Market Research analyzes that the global cystatin C assay market which was USD 224.80 million in 2023, is likely to reach USD 401.64 million by 2031, and is expected to undergo a CAGR of 7.5% during the forecast period. “Kits & Reagents” dominate the product segment of the cystatin C assay market due to the growing demand for better methods for diagnosis in patients. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Report Scope and Market Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2024 to 2031
|
|
Base Year
|
2023
|
|
Historic Years
|
2022 (Customizable to 2016-2021)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, and Pricing in USD
|
|
Segments Covered
|
By Product (Analyzers, Kits & Reagents), Method (ELISA, PETIA, IFA, CLIA, PENIA), Application (Diagnostics, Research), Sample Type (Blood, Urine), End User ( Hospitals, Clinical Laboratories, Others), Distribution Channel (Direct Tenders, Retail Sales)
|
|
Countries Covered
|
U.S., Canada, Mexico, Germany, Italy, U.K., France, Spain, Netherland, Belgium, Switzerland, Turkey, Russia, Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific, Brazil, Argentina, Rest of South America, South Africa, Saudi Arabia, U.A.E., Egypt, Israel, Rest of Middle East & Africa
|
|
Market Players Covered
|
Abbott (U.S.), Roche Diagnostics Limited (Switzerland), Siemens Healthcare GmbH (Germany), Thermo Fisher Scientific Inc. (U.S.), Randox Laboratories Ltd. (U.K.), DiaSys Diagnostic Systems GmbH (Germany), Bio-Techne (U.S.), Gentian Diagnostics ASA (Norway), Getein Biotech, Inc. (China), Agilent Technologies, Inc. (U.S.), Abcam plc. (U.K.), Sino Biological, Inc. (China), Eurolyser Diagnostica GmbH (Austria)
|
|
Market Opportunities
|
|
Market Definition
A cystatin C assay is a laboratory test used to measure the concentration of cystatin C in a person's blood. Cystatin C is a protein produced by cells in the body and is primarily found in the bloodstream. It serves as a marker of kidney function, specifically glomerular filtration rate (GFR), which is a measure of how well the kidneys are filtering waste products from the blood. The assay involves taking a blood sample and measuring the concentration of cystatin C in the serum or plasma. The results can provide valuable information to healthcare professionals in diagnosing and managing various kidney-related conditions, such as chronic kidney disease, acute kidney injury, or monitoring the effectiveness of certain treatments.
Global Cystatin C Assay Market Dynamics
Drivers
- Increasing prevalence of kidney diseases
The rising incidence of kidney diseases, including chronic kidney disease (CKD), acute kidney injury (AKI), and other renal disorders, is a significant driver of the cystatin C assay market. As kidney diseases become more common, the need for accurate and sensitive markers like cystatin C for early diagnosis and monitoring of kidney function increases.
- Growing awareness and screening programs
Increased awareness about the importance of kidney health and the implementation of screening programs for early detection of kidney diseases have led to a higher demand for kidney function tests, contributing to the growth of the cystatin C assay market.
Opportunities
- Early detection and monitoring of kidney diseases
The emphasis on early detection and monitoring of kidney diseases, including chronic kidney disease (CKD) and acute kidney injury (AKI), provides a significant opportunity for the cystatin C assay market. Early diagnosis can lead to more effective interventions and improved patient outcome.
- Increased adoption of point-of-care testing (POCT)
The development and adoption of cystatin C assays for point-of-care testing offer opportunities for quicker and convenient kidney function assessment, particularly in primary care settings, emergency departments, and remote or underserved areas.
Restraints/Challenges
- Regulatory and quality control challenges
Ensuring the quality and accuracy of cystatin C assays, as well as compliance with regulatory requirements, can be challenging for assay manufacturers and clinical laboratories.
- Research and development costs
Developing and validating new cystatin C assay technologies can be costly and time-consuming, potentially limiting the introduction of innovative solutions to the market.
This cystatin C assay market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, the impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the cystatin C assay market contact Data Bridge Market Research for an analyst brief, our team will help you make an informed market decision to achieve market growth.
Recent Developments
- In September 2022, Gentian Cystatin C and GCAL assays received IVDR (In-Vitro Diagnostic Regulation) by TÜV SÜD
- In March 2021, Roche acquired GenMark Diagnostics at USD 24.05 per share and a total transactional value of USD 1.8 billion. The acquisition strengthened Roche's Diagnostics portfolio
Global Cystatin C Assay Market Scope
The cystatin C assay market is segmented on the basis of product, method, application, sample type, end user and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Product
- Analyzers
- Kits & Reagents
Method
- ELISA
- PETIA
- IFA
- CLIA
- PENIA
Application
- Diagnostics
- Research
Sample Type
- Blood
- Urine
End User
- Hospitals
- Clinical Laboratories
- Others
Distribution Channel
- Direct Tenders
- Retail Sales
Global Cystatin C Assay Market Regional Analysis/Insights
The cystatin C assay market is analysed and market size insights and trends are provided by country, product, method, application, sample type, end user and distribution channel as referenced above.
The countries covered in the market report are U.S., Canada, Mexico, Germany, Italy, U.K., France, Spain, Netherland, Belgium, Switzerland, Turkey, Russia, rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, rest of Asia-Pacific, Brazil, Argentina, rest of South America, South Africa, Saudi Arabia, UAE, Egypt, Israel, and rest of Middle East & Africa.
North America is expected to dominate the cystatin C assay market because of the strong base of healthcare facilities, the strong presence of major players in the market, the extraordinary healthcare infrastructure, and the large pool of people having specifically kidney disorders.
Asia-Pacific is expected to witness significant growth during the forecast period of 2024 to 2031 due to the increase in government initiatives to promote healthcare, the rising health awareness among the people and growing demand for advanced medical technology for diagnosis and treatment procedures, the large population pool, and the growing demand for quality healthcare in the region.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impact the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends, and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, the impact of domestic tariffs, and trade routes are considered while providing forecast analysis of the country data.
Healthcare Infrastructure Growth Installed Base and New Technology Penetration
The cystatin C assay market also provides you with a detailed market analysis for every country's growth in healthcare expenditure for capital equipment, installed base of different kinds of products for the cystatin C assay market, the impact of technology using lifeline curves and changes in healthcare regulatory scenarios and their impact on the cystatin C assay market.
Competitive Landscape and Cystatin C Assay Market Share Analysis
The cystatin C assay market competitive landscape provides details by competitors. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width, and breadth, application dominance. The above data points provided are only related to the companies' focus related to the cystatin C assay market.
Some of the major players operating in the cystatin C assay market are:
- Abbott (U.S.)
- Roche Diagnostics Limited (Switzerland)
- Siemens Healthcare GmbH (Germany)
- Thermo Fisher Scientific Inc. (U.S.)
- Randox Laboratories Ltd. (U.K.)
- DiaSys Diagnostic Systems GmbH (Germany)
- Bio-Techne (U.S.)
- Gentian Diagnostics ASA (Norway)
- Getein Biotech, Inc. (China)
- Agilent Technologies, Inc. (U.S.)
- Abcam plc. (U.K.)
- Sino Biological, Inc. (China)
- Eurolyser Diagnostica GmbH (Austria)
SKU-